A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry disease

AimNeutralizing anti-drug antibodies (ADA) limit therapy efficacies significantly. Pegunigalsidase alfa is a newly approved drug for the treatment of Fabry disease. The increased plasma half-life due to PEGylation interferes with ADA measurements including ELISAs and serum-mediated inhibition assays...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Malte Lenders, Elisa Rudolph, Michael Rudnicki, Markus Cybulla, Eva Brand
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2026-01-01
Σειρά:	Frontiers in Immunology
Θέματα:	anti-drug antibodies drug interferences enzyme replacement therapy Fabry disease pharmacokinetics
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1724835/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!